Patients who have recovered from malignant lymphoma are at an increase
d risk of secondary acute leukemia (AL), and overt AL is frequently pr
eceded by a myelodysplastic syndrome. Although the statistical risk is
significant, only a minority of the patients will be so affected. We
have reviewed peripheral blood counts of patients with Hodgkin's disea
se (HD) and non-Hodgkin's lymphoma (NHL) treated in the Departments of
Hematology at the Edith Wolfson and Chaim Sheba Medical Centers, Isra
el. Included were only those who went into a complete remission and re
mained lymphoma free for extended periods. There were 85 patients with
HD and 36 with NHL. In both groups peripheral blood counts at diagnos
is were within the normal range. A prolonged follow-up (>4 y), during
which no further treatment was given, revealed a sustained increment o
ver time of MCV (Delta MCV) both in HD and NHL. A persistent monocytos
is in HD patients was also evident. Delta MCV was larger in HD. The di
fference at the end of the follow-up period was as follows: 10.1 fl 11.8 in HD vs 5.0 fl + 6.2 in NHL, (P < 0.001). In addition, a signifi
cant loss of the normal correlation between the MCV and levels of hemo
globin was seen at the last follow-up. The change in MCV was present i
n all treatment groups, its magnitude increasing from radiotherapy to
chemotherapy to combined radio chemotherapy. This trend is in analogy
to the risk of secondary AL which is lower in NHL vs HD. Furthermore,
it is lowest post radiotherapy and highest when both treatment modalit
ies are used. In conclusion, the data demonstrate that a form of a pro
longed subclinical effect on erythropoiesis is rather a common side ef
fect of lymphoma treatment. There is a striking analogy between the ac
quired abnormality as seen here and other variables known to be associ
ated with the subsequent risk of secondary AL. These results indicate
that the treatment of lymphoma commonly induces bone marrow aberration
s which are prolonged and of a wider spectrum than hitherto appreciate
d.